DXCM stock forecast: what analysts expect
Wall Street analysts covering DexCom, Inc. currently rate the stock a Strong Buy on average, with a mean 12-month price target of $93.44 — +2.9% versus the last price of $90.80. Targets reflect analyst opinion, not a guarantee.
DXCM historical returns
Based on monthly dividend-adjusted prices. See the full breakdown on what if you had invested in DXCM.
DXCM annual returns by year
Congress trading in DXCM
9 members of Congress have disclosed trading DXCM — 5 purchases and 9 sales worth an estimated $778,000. Most recent disclosure: May 12, 2025.
See who in Congress traded DXCM →Insider activity in DXCM
DXCM's own executives and directors have made 0 open-market purchases ($0) and 12 sales ($7.6M) in the last 90 days, per SEC Form 4 filings. Most recent: Aug 3, 2026.
| Aug 3, 2026 | Foletta Mark G | Director | Sell | $170,640 |
| Jul 31, 2026 | Foletta Mark G | Director | Sell | $160,000 |
| Jul 20, 2026 | Sayer Kevin R | Executive Chair | Sell | $2.0M |
| Jul 15, 2026 | Brown Michael Jon | EVP Chief Legal Compliance Off | Sell | $126,514 |
| Jul 6, 2026 | Sayer Kevin R | Executive Chair | Sell | $1.9M |
About DexCom, Inc.
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems for the management of diabetes and metabolic health in the United States and internationally. The company offers Dexcom G7 and G7 15 Day, an integrated continuous glucose monitoring system; Dexcom G6, a CGM system; Dexcom ONE+ to replace fingerstick blood glucose testing for diabetes treatment decisions; Stelo, a biosensor designed for adults with prediabetes and Type 2 diabetes who do not use insulin; Dexcom Share, a remote monitoring system; and Dexcom Follow application. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.
DXCM Key Statistics
DXCM in plain English
- P/E ratio (35.9) — how many dollars you pay for each $1 of DXCM's yearly profit. That's a fairly normal range.
- ROE (38.49%) — how efficiently the company turns shareholders' money into profit. Above ~20% is considered strong.
- Profit margin (20.12%) — of every $1 in sales, this is what's left as profit after all costs.
- Dividend — DXCM doesn't pay a meaningful dividend; the return here comes from the share price, not cash payouts.
DXCM stock: frequently asked questions
What is DexCom, Inc.'s stock price today?
DexCom, Inc. (DXCM) last traded at $90.80 on the NASDAQ. Over the past 52 weeks the stock has traded between $54.11 and $91.04.
Is DXCM stock a buy or a sell?
Wall Street analysts' consensus rating on DXCM is "Strong Buy", with an average 12-month price target of $93.44 — about +2.9% versus the current price of $90.80. Analyst targets are opinions, not guarantees; always do your own research.
How much would $1,000 invested in DXCM 10 years ago be worth today?
A $1,000 investment in DexCom, Inc. made 10 years ago would be worth about $3,987 today (dividends reinvested) — a total return of 299%, or 14.8% per year.
Does DXCM pay a dividend?
No — DexCom, Inc. does not currently pay a meaningful dividend. Returns for shareholders come from changes in the share price.
What is DXCM's P/E ratio?
DXCM trades at a trailing price-to-earnings ratio of 35.9, and 29.1 times expected forward earnings. The P/E ratio tells you how many dollars investors pay for each $1 of the company's annual profit.
Do members of Congress trade DXCM stock?
Yes — 9 members of Congress have disclosed trades in DXCM under the STOCK Act, totaling 5 purchases and 9 sales worth an estimated $778,000.
What is DexCom, Inc.'s ticker symbol?
DexCom, Inc. trades under the ticker symbol DXCM on the NASDAQ.
Compare DXCM with peers
Data last refreshed from public sources. Figures may be delayed. Not investment advice.